Incomplete Financial Disclosure and Error in Figure In the article by Natanson et al titled “Cell-Free Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death,” published in the May 21, 2008, issue (2008;299:2304-2312), the financial disclosure was incomplete and a figure included some incorrect numbers. In addition to the other disclosures, Dr Natanson reports being listed as a coinventor on US Provisional Application No. 60/996,530, relating to hemoglobin-based oxygen carriers. A letter describing this disclosure was published online on July 11, 2008. The provisional application expired on August 31, 2008, and Dr Natanson was not listed on the subsequent patent application.
In Figure 3, on page 2308, the first 2 rows of data are incorrect. The correct numbers for the Patient Type rows of Trauma and Elective Orthopedic or Vascular Surgery, respectively, follow: No. of Studies, 5 and 7; Total No. of Patients, 1127 and 1931; relative risks for Mortality, 1.28 (95% confidence interval, 1.00-1.64) and 1.54 (95% confidence interval, 0.92-2.58); relative risks for Myocardial Infarction, 1.8 (95% confidence interval, 0.75-4.28) and 4.06 (95% confidence interval, 1.76-9.35).
Incomplete Financial Disclosure and Error in Figure in: Cell-Free Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death. JAMA. 2008;300(11):1300. doi:10.1001/jama.300.11.1300